Nxera’s partner Holling Bio-Pharma Corp. will commercialize QUVIVIQ® in Taiwan, a market with approximately 4–5 million patients, with launch planned during 2026QUVIVIQ®…
April 10, 2026 16:09 ET | Source: Mesoblast Limited Working with Parent Project Muscular Dystrophy and the Duchenne Registry on…
Milestones underscore clinical progress and strengthen commercial foundationLOS GATOS, Calif., April 8, 2026 /PRNewswire/ -- Supira Medical, Inc. (Supira), a clinical-stage…
Offering a new, validated CCS design pathway, reducing uncertainty for cautious battery engineersNECKARSULM, Germany, March 25, 2026 /PRNewswire/ -- ENNOVI,…
NOIDA, India, March 13, 2026 /PRNewswire/ -- QuantPower, the AI-enabled algorithmic trading platform developed by Wisdom Tree Ventures Pvt. Ltd., has received…
Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism in nearly a decade1-3 HS often emerges around…
DUBAI, United Arab Emirates and TORONTO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- BioAro Inc., a biotechnology company at the forefront…
ZEISS ARTEVO 750 and ZEISS ARTEVO 850 surgical microscopes provide ophthalmic surgeons in China with end-to-end workflow integration to improve…
Sanofi’s Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease Recommendation supported by safety and efficacy…
MUMBAI, India, Jan. 24, 2026 /PRNewswire/ -- XED, a globally integrated executive education enterprise, has received in-principle approval from NSE…